risperidone has been researched along with Anorexia Nervosa in 9 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Anorexia Nervosa: An eating disorder that is characterized by the lack or loss of APPETITE, known as ANOREXIA. Other features include excess fear of becoming OVERWEIGHT; BODY IMAGE disturbance; significant WEIGHT LOSS; refusal to maintain minimal normal weight; and AMENORRHEA. This disorder occurs most frequently in adolescent females. (APA, Thesaurus of Psychological Index Terms, 1994)
Excerpt | Relevance | Reference |
---|---|---|
"The purpose of this double-blind, placebo-controlled exploratory pilot study was to evaluate the safety and efficacy of risperidone for the treatment of anorexia nervosa." | 9.15 | A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: a pilot study. ( Dodge, M; Ellert, S; Frank, G; Gardner, R; Gralla, J; Hagman, J; O'Lonergan, T; Sigel, E; Wamboldt, MZ, 2011) |
"Current Diagnostic and Statistical Manual of Mental Disorders (DSM)-5-based research provides limited data on the use of risperidone on children and adolescents with anorexia nervosa (AN) mainly in small-sample/case report studies." | 8.31 | The role of risperidone in the treatment of children and adolescents with anorexia nervosa. ( Bergonzini, L; Parmeggiani, A; Pettenuzzo, I; Pruccoli, J, 2023) |
"The purpose of this double-blind, placebo-controlled exploratory pilot study was to evaluate the safety and efficacy of risperidone for the treatment of anorexia nervosa." | 5.15 | A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: a pilot study. ( Dodge, M; Ellert, S; Frank, G; Gardner, R; Gralla, J; Hagman, J; O'Lonergan, T; Sigel, E; Wamboldt, MZ, 2011) |
"Current Diagnostic and Statistical Manual of Mental Disorders (DSM)-5-based research provides limited data on the use of risperidone on children and adolescents with anorexia nervosa (AN) mainly in small-sample/case report studies." | 4.31 | The role of risperidone in the treatment of children and adolescents with anorexia nervosa. ( Bergonzini, L; Parmeggiani, A; Pettenuzzo, I; Pruccoli, J, 2023) |
"Olanzapine is the treatment most frequently prescribed and studied with 7 randomized double-blind controlled trials." | 3.01 | Efficacy and tolerance of second-generation antipsychotics in anorexia nervosa: A systematic scoping review. ( Blanchet, C; Carretier, E; Guessoum, SB; Ludot, M; Moro, MR; Thorey, S, 2023) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (11.11) | 18.2507 |
2000's | 3 (33.33) | 29.6817 |
2010's | 3 (33.33) | 24.3611 |
2020's | 2 (22.22) | 2.80 |
Authors | Studies |
---|---|
Thorey, S | 1 |
Blanchet, C | 1 |
Guessoum, SB | 1 |
Moro, MR | 1 |
Ludot, M | 1 |
Carretier, E | 1 |
Pruccoli, J | 1 |
Bergonzini, L | 1 |
Pettenuzzo, I | 1 |
Parmeggiani, A | 1 |
Couturier, J | 1 |
Isserlin, L | 1 |
Spettigue, W | 1 |
Norris, M | 1 |
Moga, DE | 1 |
Cabaniss, DL | 1 |
Marcus, ER | 1 |
Walsh, BT | 1 |
Kahn, DA | 1 |
Hebebrand, J | 1 |
Hagman, J | 1 |
Gralla, J | 1 |
Sigel, E | 1 |
Ellert, S | 1 |
Dodge, M | 1 |
Gardner, R | 1 |
O'Lonergan, T | 1 |
Frank, G | 1 |
Wamboldt, MZ | 1 |
Mehler-Wex, C | 1 |
Romanos, M | 1 |
Kirchheiner, J | 1 |
Schulze, UM | 1 |
Fisman, S | 1 |
Steele, M | 1 |
Short, J | 1 |
Byrne, T | 1 |
Lavallee, C | 1 |
Newman-Toker, J | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa[NCT00140426] | Phase 4 | 41 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"Body Image Software (BIS) - the subject adjusts a digital image of themselves on the computer to their desired image, and also completes a task that determines their perception of their current image. Accuracy is measured by a smaller score between desired image and actual image.~Change in BIS-DL was calculated using an estimate of change in score between week 0 and week 7 derived from the mixed effect model across all time points.~There are no identifiable minimum/maximum values as there would be in a questionnaire scale. There are no subscales. Interpreting the DL occurs by referencing it to DL= 0, which would reflect a total inability to detect size differences, which has never occurred in studies using the BIS program." (NCT00140426)
Timeframe: monthly
Intervention | units on a scale (Mean) |
---|---|
Risperidone or Placebo | -0.19 |
Risperidone | -1.16 |
"Body Image Software (BIS) - the subject adjusts a digital image of themselves on the computer to their desired image, and also completes a task that determines their perception of their current image. Accuracy is measured by a smaller score between desired image and actual image.~Change in BIS -PSE was calculated using an estimate of change in score between week 0 and week 7 derived from the mixed effect model across all time points.~There are no identifiable minimum/maximum values as there would be in a questionnaire scale. Interpreting the PSE is how it compares to a PSE = 0, which is no distortion in body size." (NCT00140426)
Timeframe: monthly
Intervention | units on a scale (Mean) |
---|---|
Risperidone or Placebo | -0.32 |
Risperidone | -2.18 |
"Body Image Software (BIS) - the subject adjusts a digital image of themselves on the computer to their desired image. The BIS program calculates the difference between their actual image, and how much they have adjusted the image to represent their desired image. Accuracy is measured by a smaller score between desired image and actual image.~Change in BIS - Average Desired Thinness score was calculated using an estimate of change in score between week 0 and week 7 derived from the mixed effect model across all time points.~There are no identifiable minimum/maximum values as there would be in a questionnaire scale. . There are no subscales." (NCT00140426)
Timeframe: monthly
Intervention | units on a scale (Mean) |
---|---|
Risperidone or Placebo | 1.88 |
Risperidone | -1.42 |
"Body Image Software (BIS) - the subject adjusts a digital image of themselves on the computer using the direction to adjust their image to how they see themselves right now, this determines their perception of their current image. Accuracy is measured by a smaller score between desired image and actual image.~Change in the BIS Average Distortion score during the study was calculated using an estimate of change in score between week 0 and week 7 derived from the mixed effect model across all time points.~There are no identifiable minimum/maximum values as there would be in a questionnaire scale. There are no subscales. The BIS program calculates the difference between their actual image and the size of the image they have adjusted the digital image to based on their perception of how they see themselves right now" (NCT00140426)
Timeframe: monthly
Intervention | units on a scale (Mean) |
---|---|
Risperidone or Placebo | -0.22 |
Risperidone | 1.40 |
"change in Eating Disorder Inventory (EDI) 2-score for Body Dissatisfaction (BD).~Lower scores are better on this scale. Higher scores indicate the subject has greater body dissatisfaction. BD is one of the 8 subscales of the EDI-2. 9 of the 91 questions in the EDI-2 scale constitute this subscale. The score range is 0-27. Subjects completed the EDI-2 at baseline and monthly during study participation (range 0 to 18 weeks). Change in the BD subscale score during the study was calculated using an estimate of change in score between week 0 and week 7 derived from the mixed effect model across all time points." (NCT00140426)
Timeframe: monthly
Intervention | units on a scale (Mean) |
---|---|
Placebo | 0.82 |
Risperidone | 2.67 |
"Eating Disorder Inventory -2 - Subscale : Drive for Thinness Subscale (DT). Lower scores are better on this scale and indicate less cognitive focus on drive for thinness.~The EDI 2 is a 91 item scale with 8 subscales - (Drive for thinness, Bulimia, body dissatisfaction, ineffectiveness, perfection, interpersonal distrust, interoceptive awareness and maturity fears.). The DT subscale was used for this outcome. Respondents rate each item as usually , often, sometimes, rarely or never. Subscale scores are computed by summing all item scores for each subscale. There are 7 items in the DT subscale (questions 1,7,11,16,25,32 and 49). the subscale score range is 0-21. The EDI-2 was completed by subjects at baseline and then monthly during study participation (range 0 -18 weeks). Change in the DT subscale score was calculated using an estimate of change in score between week 0 and week 7 derived from the mixed effect model across all time points." (NCT00140426)
Timeframe: month
Intervention | units on a scale (Mean) |
---|---|
Placebo | 1.36 |
Risperidone | 3.93 |
Leptin levels were measured by serum blood draws, results reports in nanograms / ml (ng/ml). (NCT00140426)
Timeframe: Week 0 and week 7
Intervention | ng/ml (Mean) |
---|---|
Placebo | 0.88 |
Risperidone | 3.27 |
Prolactin serum blood levels, measured in nanograms / ml (NCT00140426)
Timeframe: week 0 and week 7
Intervention | ng/ml (Mean) |
---|---|
Placebo | -5.18 |
Risperidone | 38.27 |
"The Multidimensional Anxiety Scale for Children (MASC) is a self report measure completed by the subject that measures anxiety symptoms.~Higher scores indicate greater anxiety. A score of over 50 is significant for anxiety~Change in MASC scores was calculated using an estimate of change in score between week 0 and week 7 derived from the mixed effect model across all time points." (NCT00140426)
Timeframe: monthly to study end point
Intervention | units on a scale (Mean) |
---|---|
Placebo | 7.41 |
Risperidone | 7.87 |
"Color A Person Test (CAPT) - Subjects color an outlined image of a body to indicate body dissatisfaction (red (5)= very dissatisfied, Yellow, dissatisfied, black, neutral, green satisfied, blue very satisfied (1). The outline is divided into16 sections for scoring. The CAPT was completed at baseline and monthly during study participation.~Total CAPT scores were calculated by adding the total score and dividing by 16. Score range is 1-5. Lower scores indicate less body dissatisfaction.~Change in the CAPT score during the study was calculated using an estimate of change in score between week 0 and week 7 derived from the mixed effect model across all time points." (NCT00140426)
Timeframe: monthly
Intervention | units on a scale (Mean) |
---|---|
Risperidone or Placebo | 0.03 |
Risperidone | 0.22 |
"The Ease of Eating Scale (EOES) is a 14 item scale which measures Food avoidance behaviors (FABs). The scale is rated by staff observing a subject eating a meal or snack. 0 = normal eating behavior, maximum score 28.~Higher scores indicate more food avoidance behaviors, such as taking small bites, taking > 30 seconds between bites (slow eating), etc.~EOE was completed for each meal a subject ate in the program and scores were averaged for each week in the study and entered in the data base.~Change in EOES score was calculated by evaluating change over time. This measure was only used in Phase 1 of the study, for days the subjects were in the treatment program." (NCT00140426)
Timeframe: weekly up to study endpoint: reaching target weight and maintaining for 1 month
Intervention | hazard ratio (Number) |
---|---|
Placebo | 0.85 |
Risperidone | 1 |
The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time. These estimates were produced using Kaplan-Meier probabilities. (NCT00140426)
Timeframe: 0 - 18 weeks
Intervention | weeks (Mean) |
---|---|
Placebo | 10.1 |
Risperidone | 12.9 |
The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time. These estimates were produced using Kaplan-Meier probabilities. This was measured weekly from 0-18 weeks. (NCT00140426)
Timeframe: weekly
Intervention | weeks (Mean) |
---|---|
Placebo | 10.7 |
Risperidone | 8.1 |
3 reviews available for risperidone and Anorexia Nervosa
Article | Year |
---|---|
Efficacy and tolerance of second-generation antipsychotics in anorexia nervosa: A systematic scoping review.
Topics: Adolescent; Adult; Anorexia Nervosa; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Ol | 2023 |
Psychotropic Medication for Children and Adolescents with Eating Disorders.
Topics: Adolescent; Anorexia Nervosa; Avoidant Restrictive Food Intake Disorder; Binge-Eating Disorder; Buli | 2019 |
Atypical antipsychotics in severe anorexia nervosa in children and adolescents--review and case reports.
Topics: Adolescent; Anorexia Nervosa; Antipsychotic Agents; Benzodiazepines; Child; Dibenzothiazepines; Fema | 2008 |
1 trial available for risperidone and Anorexia Nervosa
Article | Year |
---|---|
A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: a pilot study.
Topics: Adolescent; Adult; Anorexia Nervosa; Antipsychotic Agents; Body Image; Body Weight; Child; Double-Bl | 2011 |
5 other studies available for risperidone and Anorexia Nervosa
Article | Year |
---|---|
The role of risperidone in the treatment of children and adolescents with anorexia nervosa.
Topics: Adolescent; Anorexia Nervosa; Antipsychotic Agents; Body Mass Index; Child; Feeding and Eating Disor | 2023 |
Religious delusions in an evangelical Christian woman with anorexia nervosa.
Topics: Adult; Anorexia Nervosa; Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Female; Hospitaliz | 2009 |
Pharmacotherapy of anorexia nervosa: more questions than answers.
Topics: Anorexia Nervosa; Antipsychotic Agents; Female; Humans; Risperidone | 2011 |
Case study: anorexia nervosa and autistic disorder in an adolescent girl.
Topics: Adolescent; Anorexia Nervosa; Antipsychotic Agents; Autistic Disorder; Behavior Therapy; Combined Mo | 1996 |
Risperidone in anorexia nervosa.
Topics: Adult; Anorexia Nervosa; Antipsychotic Agents; Child; Delusions; Dose-Response Relationship, Drug; F | 2000 |